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Effects of acute and chronic dosing of NSAIDs in patients with renal
insufficiency. Administration of nonsteroidal anti-inflammatory drugs
(NSATDs) to patients with chronically impaired renal function has been
reported to cause abrupt and sustained reductions in rcnal plasma flow
(RPF), glomerular filtration rate (OFR), and solute and water excretion
in association with decreased renal prostanoid production. However,
the time course of these acute effects and whether they are sustained
during chronic exposure to the NSAIDs are unknown. Accordingly,
using standard clearance and balance techniques, we investigated the
effects of acute (zero to four hours) aod chronic (five days) oral
administration of two different NSAIDs on renal function in patients
with stable, mild to moderate chronic renal insufficiency (CR1) and in
normal subjects. In patients, acute oral administration of ketoprofen
(K) and indomethaein (I) resulted in significant decreases in GFR (K:
from 36 3 to 20 4 mI/mm, P 0.001; I: from 37 6 to 30 7
mI/mm, p 0.032; in RPF (K: from 194 21 to 146 21 mI/mm, P =
0.002; I: from 222 33 to 147 18 mI/mm, P = 0.016); and in urinary
POE, excretion (K: from t).6tl 0.25 to 0.08 0.02 ng/min, P = 0.05;
I: from 0.34 0.06 to 0.18 0.06 ng/min, P = 0.042). Fractional
excretion of sodium chloride and fractional free water clearance
(CH2O/C1) also decreased significantly after both agents. In normal
subjects, OFR and RPF were not significantly decreased after acute
dosing, whereas urinary POE2 and fractional excretions of NaCl and
free water decreased significantly. After chronic administration of both
agents to patients, RPF had returned to control levels while OFR was
slightly decreased after K but not I administration. Acute superimposed
on chronic NSAID administration resulted in mild but nonsignificant
decreases in RPF, OFR, and CH2O/CIN, whereas fractional excretion of
NaC1 and urinary POE2 excretion decreased significantly. Daily, 24
hour ereatinine clearance measurements decreased slightly but returned
toward control levels by day five (K: from 42 4 to 36 6, NS and I:
from 56 8 to 53 9, NS) whereas daily urinary POE2 excretion was
still decreased from pre-drug control values at day five (K: from 0.48
0.17 to 0.19 0.05, P = 0.11, 1 from 0.37 ii 0.06 to 0.17 0.04, P =
0.015). Body weight, sodium balance and blood pressure were not
significantly altered. These data indicate that acute administration of
NSAIDs to patients with chronic renal insufficiency results in decreases
in RPF and OFR which are transient and reversible within the time
frame of a standard dosing regimen. it appears that after chronic
NSAID administration a superimposed single dose of NSAID causes a
similar transient effect that may be less in magnitude.
arterial blood volume has been clearly demonstrated. In pa-
tients with cirrhosis, inhibition of renal cyclo-oxygenase activ-
ity by oral administration of various nonsteroidal anti-inflam-
matory drugs (NSAIDs) is accompanied by sharp decreases in
renal blood flow, glomerular filtration rate, and solute and water
excretion [1, 21. Under these circumstances, it has been sug-
gested that renal prostanoids (particularly, prostacyclin) exert a
tonic vasodilatory effect which is subsequently attenuated by
cyelo-oxygenase inhibitors, leaving the renal circulation vulner-
able to the effects of extant vasoconstrictors (such as, angio-
tensin II and eatecholamines). In addition, oral administration
of renal eyclo-oxygenase inhibitors has decreased renal perfu-
sion and solute and water excretion in patients with mild,
chronic—intrinsic renal disease (in the absence of reduced
effective arterial blood volume) [3—6]. Because of these obser-
vations, many consider a diagnosis of renal insufficiency of any
degree to represent a contraindication to administration of
NSAIDs. However, it is not clear whether the deleterious
effects of NSAIDs on renal function are sustained during
chronic, persistent inhibition of baseline renal prostaglandin
production in all patients with mild—to—moderate chronic renal
insufficiency. This possibility is an important clinical issue
because of the widespread use and efficacy of this class of
anti-inflammatory agenls.
The purpose of the present study was to examine the effects
of acute and chronic inhibition of renal eyelo-oxygenase activ-
ity on renal function in patients with mild, chronic renal
insufficiency of diverse pathophysiological origin. The results
suggest that each administered dose of N SAID causes a tran-
sient, reversible decrease in renal hemodynamies and solute
and water excretion that may dampen with time. Overall, in
patients with mild intrinsic renal insufficiency, use of NSAIDs
had negligible adverse effects.
Methods
The importance of renal prostanoids in maintaining renal
hemodynamies in humans under conditions of reduced effective Subjects
We performed a total of 30 studies, Eight normal subjects
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(mean age, 27 yrs, mean wt, 75.8 kg) completed two studies
each, one with indomethaein and one with ketoprofen. The
order of studies was random and at least one month elapsed
between them. The normal volunteers were receiving no med-
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Table 1. Patient characteristics
Creatinine
clearance
Patient Age/sex Wt ml/min/
number yrs kg 1.73m2
22 57M 52 66
23 43 M 75 47 Hypertension
S/P Subarachnoid
hermor-
rhage
24 59 M 109 31 Hypertension
Gout
Angina
25 28 F 61 41 Hypertension
Diabetes
26 24 F 84 75 Focal
Glomeru-
Iosclerosis
27 38 F 70 83 Hypertension Methyldopa
Polycystic
kidney
disease
28 34 M 75 33 Hypertension Hydralazine
Gout Propranolol
Furosemide
Allopurinol
Colchicine
29 49 M 112 77 Hypertension Hydralazine
Diabetes Propranolol
Furosemide
Insulin
31 34 F 125 33 Hypertension Clonidine
Diabetes Furosemide
Insulin
33 55 M 104 39 Hypertension Furosemide
Diabetes Hydralazine
Clonidine
Insulin
34 38 M 70 42 Hypertension Furosemide
Minoxidil
Captopril
Clonidine
35 59 M 63 19 Hypertension Furosemide
Clonidine
Propranolol
a Patients who participated in two studies
ications, including non-prescription drugs. Twelve patients with
chronic renal insufficiency of various etiologies underwent
fourteen studies (eight with indomethacin and six with
ketoprofen). Their demographics, diagnoses, level of renal
function and concomitant medications are listed in Table 1.
They were maintained on stable doses of all chronic medica-
tions. On the days of the clearance studies, all medications were
withheld until completion of those studies. Their renal function
had been stable for at least six months, with no history of acute
renal failure or intermittent dialysis within the past year. None
of these patients ingested any NSAIDs for at least one month
prior to study.
Study design (Fig. 1)
Subjects were admitted to the General Clinical Research
Center (GCRC) for the duration of the study. All study subjects
ingested a whole—food diet containing constant amounts of
Nat, K and Cl-. The sodium content for all subjects except
one (100 mEq/day) was 150 mEq/day. The patient with renal
insufficiency receiving 100 mEq did so by miscalculation. His
diet was constant and his response did not differ from the other
subjects. Potassium intake ranged from 60 to 80 mEq/day
among patients but was constant within an individual patient. I
one patient, K intake was less on the last day of study. Data
concerning potassium homeostasis for this patient was ex-
cluded.
The first four days of study were an equilibration and control
period. Daily 24 hour urine collections were obtained for
quantitation of electrolytes, creatinine, and PGE2. Urine was
refrigerated immediately after voiding to minimize spontaneous
degradation of PGE2. Daily fasting, morning serum samples
were obtained for measurement of electrolytes and creatinine.
On the morning of the fifth day a clearance study was
performed (Fig. 1). Meals were held until the completion of all
collections during this study. Intravenous catheters were placed
in each forearm, one for obtaining blood samples and one for
administration of marker compounds. A loading dose of inulin
and para-aminohippurate (PAH) was administered, followed by
continuous infusions calculated to maintain serum concentra-
tions of approximately 25 and 1.5 mg%, respectively. To
establish a water diuresis, subjects simultaneously drank a
water load of 20 ml/kg body weight. Subsequently, water was
ingested at a rate sufficient to replace urine output (plus 1
ml/min to replace insensible losses). After a 45 minute equili-
bration period, three to four, twenty—minute urinary control
collections were obtained with midpoint serum samples. Either
indomethacin (50 mg) or ketoprofen (50 mg) was then adminis-
tered by mouth followed by eight experimental collections.
Serum and urine samples were assayed for electrolytes, inulin,
PAH, and creatinine; urine was also measured for PGE2.
On days five through ten, subjects received indomethacin 50
mg every eight hours or ketoprofen 50 mg every six hours with
daily measurements as in the control periods. These doses and
dosing intervals were chosen to duplicate those used clinically.
On the morning of day 11, a repeat clearance study was
performed. Before the patient was to receive the morning dose
of NSAID, control collections were obtained followed by the
Diagnoses
Polyarteritis
nodosa
-4— 150 mEq Na Diet
4 NSAID—
I I LJDay
20'
Clearance
periods
Concomitant
medications
Hydrochlorothia-
zide
Cyclophospha-
mide
Minoxidil
Nadolol
Hydralazine
Propranolol
Furosemide
Isosorbide dini-
trate
Allopurinol
Clonidine
Furosemide
Insulin
None
Control
I
N SAID
Fig. 1. Schematic of the study design.
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Table 2. Effects of indomethacin on renal function in patients with chronic renal insufficiency
CIN
mi/ruin
CPAH
mi/ruin
CH2o/CIN
%
CcI÷CH20/CIN
%
FENa
%
FEc1
%
U80,2
ng/min
Acute clearance study
37
6
30
7
0.032
34
4
31
5
0.139
222
33
147
18
0.016
233
49
210
32
0.700
8.8
2.0
5.1
2.0
0.021
4.9
1.0
5.6
2.0
0.671
11.0
2.0
6.0
3.0
0.020
7.2
2.0
6.6
2.0
0.728
1.9
0.5
0.8
0.3
0.010
2.1
0.6
1.1
0.2
<0.05
1.8
0.5
1.0
0.4
0.039
2.5
0.6
1.1
0.3
0.022
0.34
0.06
0.18
0.06
0.042
0.38
0.15
0.21
0.07
<0.05
No drug control
5EM
Peak effect
5EM
P value
Chronic clearance study
Chronic treatment
control SEM
Peak effect
5EM
P Value
first dose of medication administered that day with subsequent
experimental collections. Hence, control collections during this
second clearance study reflected renal function under the
influence of chronic exposure to these NSAIDs, while the
experimental collections assessed acute effect superimposed
upon the background of chronic exposure.
Analytical methods
Sodium and potassium were measured with ion—specific
electrodes, chloride by potentiometric titration and creatinine
by the Jaffe reaction with an autoanalyzer (Beckman Astra 8,
Beckman Instruments, Inc., Fullerton, California, USA); inulin
and PAH were measured with an autoanalyzer (Technicon
Instruments Corporation, Tarrytown, New York, USA);
osmolality was measured using freezing point depression with a
mieroosmometer (Precision Systems, Sudbury, Massachusetts,
USA). Urinary POE2 was measured by radioimmunoassay
using the method of Dray, Charbonnel, and Maelouf [7] as
modified by Campbell, Gomez—Sanchez, and Adams [81.
Briefly, 2 ml of urine was acidified to pH 3.0 with glacial acetic
acid and passed through a 6 ml Baker C13 extraction column
that had been previously washed with ethanol and water. The
column was washed successively with 5 ml of 15% ethanol in
water and toluene and the PGs were eluted with 2 ml of ethyl
acetate. This eluate was evaporated to dryness under a stream
of nitrogen and further purified by silicic acid chromatography
[9]. The PG containing fraction was measured by radio-
immunoassay. One—tenth milliliter of the reconstituted fraction
was mixed with 0.t ml of 3H-PG and 0.1 ml' of the diluted
antiserum. After incubation overnight at 4°C, the bound and
free PGs were separated with dextran—coated charcoal and the
bound counts were estimated by liquid scintillation spectrome-
try. The results were corrected for recovery and expressed as
picograms per milliliter, With each assay a water blank was
assessed. To avoid any artifact of increased urinary volumes, if
a water blank was elevated, the assay was discarded and
repeated.
I)ata analysis
During each clearance study, the effects of indomethacin or
ketoprofen on clearances of inulin and PAR, on fractional
excretions of electrolytes, on free water clearance, and on
urinary PGE2 were assessed. Control values represent the mean
of two to three stable collections during the control periods.
Values for the effects of NSAID represent the mean of three
collections obtained immediately before, during, and after the
peak effect as represented by the maximal decrease in sodium
excretion. Hence, these three collections encompass the max-
imum effects of the drug. On a daily basis, effects were assessed
on 24 hour creatinine clearance and electrolyte excretion and on
serum concentrations of creatinine and potassium. Hence, the
clearance studies represent assessment of acute effects of the
NSAID with both initial dosing and with chronic therapy. In
contrast, the daily 24 hour assessment represents an integrated
function of the overall effects of chronic exposure to the
NSAID. Standard clearance formulae were used to calculate
fractional free water clearance and fractional chloride plus free
water clearance.
Results of statistical analyses using paired Student's t-tests
were considered significant if P < 0.05.
Results
Clearance studies in patients with chronic renal insufficiency:
renal hemodynamics
During the acute clearance study (Tables 2 and 3), both mean
glomerular filtration rate (GFR) and mean renal plasma flow
(RPF) decreased significantly after acute administration of
indomethacin (P = 0.032 for GFR and P 0.016 for RPF)
(Table 2) and of ketoprofen (P 0.001 for GFR and P = 0.002
for RPF) (Table 3).' After chronic administration of both
NSAIDs (Tables 2 and 3), mean GFR and RPF again decreased
with superimposed acute dosing, but the decrement did not
achieve statistical significance (P 0.139 for indomethacin for
GFR and P = 0.700 for RPF; P = 0.096 for ketoprofen for GFR
and P = 0,326 for RPF). Thus, the effect of individual doses of
both NSAIDs to decrease GFR and RPF appeared to be blunted
during chronic therapy.
Comparison of the two control periods as shown in Figure 2
allowed assessment of baseline renal function compared to
renal function under the influence of chronic exposure to the
'The peak decrement in renal function occurred from 60 to 230
minutes after indomethacin and from 80 to 160 minutes after ketoprofen.
NSAIDs in renal disease 763
Table 3. Effect of ketoprofen on renal function in patients with chronic rena! insufficiency
CIN
mi/mm
CPAH
mi/mm
CH20/CIN% CcI+CH20/CIN%
FENa
%
FE1
% UN3E2ng/min
Acute clearance study
No drug control 36 194 5.9 8.3 2.4 2.6 0.60
SEM 3 25 0.7 1.0 0.9 0.8 0.25
Peak effect 20 146 2.8 3.2 0.4 0.4 0.08
SEM 4 21 0.7 0.7 0.1 0.1 0.02
P value 0.001 0.002 0.05 0.018 <0.05 0,039 <0.05
Chronic clearance study
30 183 11.7 15.8 4.3 3.9 0.43Chronic treatment
control SEM 4 28 1.0 2.0 0.9 0.8 0.14
Peak effect 22 156 7.8 10.0 1.9 2.0 0.22
SaM 2 32 2.0 2.0 0.8 1.0 0.08
P Value 0.096 0.326 0.059 0.031 0.004 0.025 0.207
NSAID. After chronic exposure to indomethacin, steady—state
mean GFR and mean RPF did not differ significantly from the
pre-drug initial control values (P = 0.652 and P = 0.894,
respectively). With ketoprofen, chronic therapy resulted in a
small, but significant decline in GFR from 36 3 to 30 4
mllmin (P = 0.009). In contrast, RPF was not significantly
decreased (P = 0.683).
In summary, acute administration of both agents resulted in a
reversible decrease in GFR and RPF, while in the steady—state,
RPF and GFR (with indomethacin) returned to levels not
different from the pre-drug control value.
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Solute and water excretion
Mean fractional free water clearance (CH2O/CIN), an index of
distal nephron sodium chloride reabsorptive capacity, de-
creased significantly after acute oral administration of keto-
profen (P = 0.05) and indomethacin (P = 0.021) (Tables 2 and
3). In contrast, CH2O/CIN did not change significantly after
chronic administration of either NSAID (P = 0.671 for indo-
methacin, P = 0.059 for ketoprofen) (Tables 2 and 3). After
acute administration of both NSAIDs and after chronic admin-
istration of ketoprofen, but not indomethacin, mean fractional
chloride plus free water clearance (Cci + CH2O/CIN), an index
of distal nephron NaC1 delivery, decreased significantly. As
shown in Figure 3, CH2O/CIN appeared to be a linear function
of Cc1 + CH2O/CIN, indicating that the decreased distal NaCl
reabsorptive capacity after NSAID administration was due to a
decrease in distal NaC1 delivery. Similar results have been
previously observed in normal subjects acutely administered
NSAIDs under similar experimental conditions [10].
Fractional excretion of sodium and chloride decreased signif-
1.0
0.8
0.6
0.4
0.2
250
200I
0 150
40C
E 30
0
20
10
4 8 12 16 4 8 12 16
CcI+CHo
CI,,
Fig. 3. Effects of indomethacin and of ketoprofen on urinary dilution in
patients with renal insufficiency. Symbols are: (0) no drug control; (•)
acute drug effect; () chronic treatment control; (A) chronic drug
effect.
No drug Chronic No drug Chronic
control NSAID control NSAID
Fig. 2. Control values for inulin and PAH clearances and urinary
excretion of PGE2 when receiving no NSAID compared to chronic
exposure to the NSAID, Symbols are: (0) ketoprofen; (Li) in-
domethacin.
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Fig. 4. Effects of iridornethacin ond of ketoprofen on sodium and
chloride excretion in renal insufficiency. Symbols are: (C)) ketoprofen;
(A) indomethacin.
icantly after both acute and chronic drug administration (Tables
2 and 3, Fig. 4).
in summary, after acute NSAID administration, fractional
distal solute delivery (Cr1 + CHZO/CtN), diluting capacity
(CH2O/CtN), and fractional cxcrction of sodium and chloride all
decreased in parallel. After chronic NSAID administration,
diluting capacity was not significantly altered by a superim-
posed acute dose of indomethacin, whereas a significant de-
crease in distal delivery and a fall in diluting capacity were
observed after ketoprofen. Importantly, fractional excretion of
sodium and chloride decreased after both acute and chronic
drug administration. Taken together with the hemodynamic
data, there appears to be a dissociation of the effects of NSAIDs
with chronic as opposed to acute therapy; namely, after chronic
exposure, effects on sodium and chloride excretion persist
unabated while effects on RPF and UFR and on fractional free
water clearance lessen.
Prostaglandin metabolism
Urinary PGE2 excretion decreased significantly after acute
administration of both agents as presented in Tables 2 and 3 (P
= 0.042 for indomethacin, P C 0.05 for ketoprofen). After
chronic drug administration, PUB2 excretion also decreased
after acute dosing (P C 0.05 for indomethacin); however, after
that ketoprofen did not achieve statistical significance (P =
0.207). In general, then, each dose of N SAID caused a decline
in urinary POE2 excretion, thereby following a similar pattern
as occurred with solute excretion.
Of note is the finding that during the control period of the
clearance study after chronic dosing with either drug, the POE2
excretion rate did not differ significantly from the value ob-
served during the control period of the acute clearance study (P
= 0.864 for indomethacin, P = 0.589 for ketoprofen) (Figure 2).
Hence, the basal, morning urinary excretion rate of POE7 on
the fifth day of NSAID administration was the same as the basal
morning excretion rate prior to NSAID administration.
Clearance studies in normal subjects
Renal hemodynamics. During the acute study, indomethacin
caused a slight, but significant, decrease in mean RPF (P =
0.037), but mean GFR was not substantially altered (P 0.100)
(Table 4, Fig. 5). Ketoprofen did not significantly affect GFR (P
= 0.703) or RPF (P = 0.172) (Table 5, Fig. 5).
The control values of GFR and RPF during chronic adminis-
tration of either drug did not differ significantly from the control
periods of the acute studies (Fig. 2) (P = 0.656 and P = 0.622,
respectively for indomethacin; P = 0.364 and P = 0.865,
respectively for ketoprofen).
After chronic administration of ketoprofen, a significant
decrease in GFR (P = 0.012) was observed with superimposed
acute dosing in the absence of a significant change in RPF (P =
0.247). During chronic indomethacin therapy, acute administra-
tion did not significantly affect either GFR (P = 0.375) or RPF
(P 0.753).
Solute and water handling. Both fractional free water clear-
ance (CH2O/CIN) and distal delivery of sodium (Cci
CH2O/C1N) decreased after administration of both NSAIDs in
the acute and in the chronic study periods (Tables 4 and 5).
Similar to findings in the patients with renal insufficiency, the
decrease in CH2O/CtN was proportional to the decrease in Cci +
CH2O/CtN, during all conditions (data not shown).
Balance studies
Patients with renal insufficiency. During chronic oral admin-
istration of indomethaein and ketoprofen, a non-statistically
significant decrease in creatinine clearance of 15 to 20% (from
control levels) was observed (Fig. 6). Serum creatinine in-
creased in association with the observed decrease in creatinine
clearance (Fig. 6).
Patients administered ketoprofen had a mean net cumulative
sodium balance at the end of the final study day of +45 18.9
mEq (N S), and patients receiving indomethacin had a mean net
cumulative sodium balance of +4.2 15 mEq (NS). Mean body
weight was slightly, but not significantly, increased in patients
after chronic administration of both agents (data not shown).
Net cumulative potassium balance occurred in patients after
both agents by day six of the study (indomethacin -I- 29 3.0
mBq, ketoprofen + 22 8.6 mEq). Mild hyperkalemia oc-
curred in patients after both agents (Fig. 7). With ketoprofen,
serum potassium increased from a control value of 4.35 0.15
to a maximal concentration of 4.97 0.27 (P 0.038); with
indomethacin a rise from 4.03 0.12 to 4.75 0.18 (P < 0.001)
occurred.
Daily urinary PUB2 excretion was decreased as compared to
the control value after chronic administration of both agents
(for indomethacin, 0.37 0.06 vs. 0.17 0.04, P 0.015; for
*
*
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Table 4. Effect of indomethacin on renal function in normal subjects
CIN
mi/mm
CPAH CH20/CIN Ccl÷CH20ICIN
mi/mm %
FENa
%
FE1
%
UPGE2
ng/min
Acute clearance study
No drug control 104 609 10.3 11.2 2.0 1.8 0.34
SEM 7 35 1.0 1.0 1.0 0.5 0.06
Peak effect 98 549 7.0 7.6 0.3 1.0 0.18
SEM 8 28 0.9 0.9 0.04 0.4 0.06
P value 0.100 0.037 0.002 0.001 <0.01 0.001 0.025
Chronic clearance study
100 591 8.5 10.5 1.2 1.3 0.59Chronic treatment
control SEM 9 50 0.8 1.0 0.1 0.2 0.15
Peak effect 95 573 7.4 8.1 0.7 0.8 0.35
SEM 11 35 1.0 1.0 0.1 0.1 0.07
P Value 0.375 0.753 0.223 0.025 0.004 0.040 <0.05
Table 5. Effect of ketoprofen on renal function in normal subjects
CIN
mi/mm
CPAH Cn2o/CIN Ccl±CH,o/CIN
mi/mm % %
FENa
%
FEc1
% UPGE2ng/min
Acute clearance study
No drug control 115 599 9.0 9.8 0.8 0.9 0.71
SEM 6 27 0.8 0.9 0.1 0.2 0.22
Peak effect 111 565 6.0 6.4 0.3 0.3 0.29
SEM 9 29 0.8 0.8 0.03 0.04 0.07
P value 0.703 0.172 0.054 0.018 0.001 0.004 <0.02
Chronic clearance study
106 594 9.8 11.5 1.5 1.6 0.50Chronic treatment
control SEM 7 38 0.7 0.8 0.2 0.3 0.19
Peak effect 89 567 7.2 7.8 0.5 0.5 0.19
SEM 7 32 0.9 1.0 0.1 0.1 0.07
P Value 0.012 0.247 0.007 0.002 <0.001 0.001 0.173
ketoprofen, 0.48 0.17 vs. 0.19 0.05, P = 0.11). This
decrease was sustained throughout the entire period of study
(Fig. 7).
Overall, then, chronic dosing with both NSAIDs resulted in
decreased 24 hour urinary PGE2 excretion accompanied by
positive potassium balance with hyperkalemia and 15 to 20%
decreases in creatinine clearance.
Normal subjects (data not shown). Creatinine clearance was
not significantly altered after either agent in normal subjects.
Body weight, serum potassium, and serum creatinine were not
significantly affected. Both cumulative potassium and cumula-
tive sodium balance were not significantly different from zero.
Discussion
The results of the present studies indicate that in patients
with mild chronic renal insufficiency, acute inhibition of renal
cyclo-oxygenase activity by two different nonsteroidal anti-
inflammatory agents decreased renal plasma flow and glomeru-
lar filtration rate in association with decreased solute excretion
and diluting capacity (Tables 2 and 3, Fig. 4). Similarly, after
chronic administration of these agents to patients with renal
insufficiency, solute excretion decreased shortly after adminis-
tration of a routine dose. Changes in GFR and RPF followed the
same trend but the decrease appeared to be attenuated.
An important clinical finding in the present study was the
maintenance of renal perfusion and solute excretion at pre-drug
control levels during the period of chronic administration of
NSAIDs (Fig. 2). These observations coupled with those noted
above imply that the effects of the NSAIDs were transient and
fully reversible with the dose and dosing interval employed.
Moreover, the daily 24 hour urinary data which represent an
integrated function of the effects of these NSAIDs on renal
function indicated only minor overall effects on creatinine
clearance, and urinary sodium excretion (Fig. 6). These data
indicate that the transient decrement in renal hemodynamics
and in solute excretion that occurs with each dose is not
quantitatively sufficient to cause a cumulative decrease in GFR
or in sodium excretion. In contrast, the summated individual
decrements in potassium and in PGE2 excretion were of suffi-
cient magnitude to result in mild but statistically significant
increases in serum potassium concentrations and decreases in
total PGE2 excretion.
These findings have important clinical implications, for they
imply that patients comparable to those studied can tolerate
some dosing regimens of NSAIDs. Caution must be exercised,
however, in extrapolation of these findings to other settings. It
must be emphasized that larger doses of the currently tested
drugs might cause sufficient individual decrements in renal
function to have an overall deleterious effect when summated.
A similar scenario might be expected with doses of other
NSAIDs that may be more potent. Finally, long acting
NSAIDs, sustained release formulations, or regimens with
short dosing intervals and thereby more persistent effects,
might cause sufficiently prolonged effects to prevent recovery
between doses and cause an overall adverse effect. These
possibilities need further study. However, it is clear from our
T0
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Fig. 5. Effects of indomethacin and of ketoprofen on renal hemody-
namics and PGE2 excretion in normal subjects. Symbols are the same
as Figure 4.
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Fig. 6. Daily creatinine clearance and serum creatinine during chronic
dosing of indomethacin and ketoprofen. Brackets represent the SEM for
each group. Symbols are the same as Figure 4.
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Fig. 7. Daily serum potassium Concentrations and urinary excretion of
PGE2 during chronic dosing of indomethacin and ketoprofen. Symbols
are the same as Figure 4.
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data that many patients with renal insufficiency can safely
receive NSAIDs if their renal function is closely monitored.
The present studies suggest that patients with fixed renal
parenchymal disease behave differently from patients with
reduced effective arterial blood volume such as cirrhotics. In
the latter group, a tendency for more severe and sustained
decreases in renal hemodynamics, PGE2 production and solute
excretion after chronic administration of NSAIDs has been
reported [1, 21. A similar response to that of the cirrhotic patient
with ascites has also been observed in patients with chronic—
congestive heart failure and during experimental states of
sodium depletion in man and animals [11—22]. In these condi-
tions, an apparent decrease in effective arterial blood volume
presumably operates to induce renal vasoconstriction which is
counterbalanced by production of renal prostaglandins at a rate
greater than that found in normal subjects. In contrast, in our
patients with chronic renal insufficiency, who do not have a
concomitant decrease in effective arterial blood volume while
ingesting a liberal sodium intake, persistent inhibition of renal
cyclo-oxygenase activity might not be expected to cause per-
sistent renal functional impairment. It is important to empha-
size that the superimposition of sodium depletion via diet,
diuretics, etc., would probably also increase the susceptibility
of our study group to the adverse effects of NSAIDs.
Interestingly, previous studies in humans have demonstrated
that chronic oral administration of indomethacin to patients
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with mild—to—moderate chronic renal insufficiency for two to
three days results in mild, reversible reductions in glomerular
filtration rate [4, 5]. Our data are consistent with these previous
observations. On the other hand, the findings in the present
studies are in apparent conflict with those of Ciabattoni et al,
who demonstrated that chronic administration of ibuprofen was
associated with a persistent depression of renal plasma flow and
creatinine clearance when administered to patients with chronic
glomerular disease [61. The disparity between our findings and
those of Ciabattoni et al may relate to the nature of the chronic
renal impairment in the study groups. In their study, all patients
had chronic glomerulonephritides whereas our patients had
renal diseases predominantly associated with hypertension and
diabetes. Their patients conceivably may have had a pre-renal
component to the pathophysiology of their disease process
which might have rendered them more susceptible to the
adverse effects of PG inhibition.
An intriguing observation of our study that must be viewed as
preliminary is the apparent attenuation with time of the effect of
a single dose of NSAID on renal hemodynamics while the
magnitude of effect on solute excretion was unchanged. It is
conceivable that this discrepancy reflects different pools of
PGs. The sensitivity of the renal vasculature to one or more
cyclo-oxygenase metabolites of arachidonic acid may increase
when the prevailing synthetic rate is reduced. Such a mecha-
nism might operate if renal cell receptor density or affinity for
these prostaglandins were to increase during chronic NSAID
administration. In keeping with this formulation, the impact of
an acute dose of NSAID might be reduced after chronic dosing
as compared to the effects observed after an initial dose (Tables
2 and 3). Finally, it may be speculated that enhanced production
of a non-cyclo-oxygenase metabolite (or metabolites) of arachi-
donic acid with vasodilator action (such as a lipoxygenase
metabolite) may mediate a compensatory increase in RPF after
cyclo-oxygenase is inhibited. Our results would imply that such
scenarios were not operative in regards to the pool of PGs
affecting solute homeostasis. These possibilities will require
further investigation.
It is important to note that in our patient group, the mean
urinary PGE2 excretion rate was not significantly different from
that observed in normal subjects. This finding suggests that an
enhanced production rate of PGE2 does not occur in patients
with fixed loss of renal mass. It is possible that certain forms of
renal disease, such as lupus nephritis, may be associated with
an enhanced production of PGE2 which mediates a compensa-
tory increase in renal blood flow in this form of chronic renal
insufficiency [23, 241. Whether a urinary PGE2 excretion rate in
patients that is not different from normal subjects represents a
relative increase in PGE2 production per nephron that is nec-
essary for maintenance of renal hemodynamics and solute
excretion is not known.
A clinically important observation in this study was the
consistent development of hyperkalemia (Fig. 7). The develop-
ment of hyporeninemic hypoaldosteronism owing to a decrease
in prostaglandin—sensitive renin secretion during chronic ad-
ministration of NSAIDs in patients with chronic renal insuffi-
ciency has been demonstrated [25—27]. Hypoaldosteronism in
this circumstance may be of sufficient magnitude to result in
impaired renal potassium secretion and chronic hyperkalemia
as we observed [28—301.
In conclusion, routine doses of indomethacin and ketoprofen
administered to patients with mild chronic renal insufficiency
maintained on a liberal salt intake resulted in mild, non-
sustained decrements in renal hemodynamics. In addition,
administration of these agents for five days resulted in only mild
sodium retention when dietary sodium intake was constant and
normal. In this type of patient, chronic administration of these
agents to treat coincident inflammatory disorders may be car-
ried out safely when dietary sodium is not restricted and when
serum potassium and creatinine clearance was monitored
closely.
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